Literature DB >> 33977793

Vasopressor Discontinuation Order in Septic Shock With Reduced Left Ventricular Function.

Ashley Taylor1,2, Timothy Jones2, Christy Cecil Forehand1,2, Susan E Smith2, Hannah Dykes2, Andrea Sikora Newsome1,2.   

Abstract

BACKGROUND: The optimal vasopressor management for septic patients with left ventricular (LV) dysfunction has not been well established, and current evidence is conflicting regarding the optimal vasopressor discontinuation order.
OBJECTIVE: The objective was to evaluate the impact of LV dysfunction on the hemodynamic management of septic shock by assessing the incidence of clinically significant hypotension after vasopressor discontinuation.
METHODS: In this single-center, retrospective cohort study, adult patients were included if they met the Sepsis-3 definition of septic shock, had LV dysfunction (defined as an ejection fraction ≤40%), and received norepinephrine and vasopressin as the last vasopressors discontinued. The primary outcome was the incidence of clinically significant hypotension following discontinuation of vasopressin or norepinephrine. Clinically significant hypotension was defined as a MAP less than 60 mmHg and the need for either: 1) the reinstitution of the previously discontinued agent at any dosage, 2) the receipt of at least 500 mL of a crystalloid at a rate of at least 500 mL/hour, 3) or the receipt of at least 25 grams of albumin 5% at a rate of at least 25 gram/hour. Secondary outcomes included intensive care unit (ICU) and hospital lengths of stay, and ICU and hospital mortality.
RESULTS: A total of 78 patients met inclusion criteria, with 37 patients having vasopressin discontinued first and 41 having norepinephrine discontinued first. Clinically significant hypotension occurred in 28 patients (76%) following the discontinuation of vasopressin, compared to 28 patients (81%) following the discontinuation of norepinephrine (p = 0.61). ICU length of stay was 9 days in the vasopressin discontinued first cohort, compared to 15 days in the norepinephrine discontinued first cohort (p = 0.01). There was no statistically significant difference in mortality observed.
CONCLUSION: The discontinuation order of norepinephrine and vasopressin did not impact the incidence of clinically significant hypotension in patients with septic shock and LV dysfunction, but may influence ICU length of stay, although other factors may have impacted this finding.

Entities:  

Keywords:  heart failure; left ventricular dysfunction; norepinephrine; septic shock; vasopressin

Year:  2021        PMID: 33977793      PMCID: PMC8586033          DOI: 10.1177/08971900211015080

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  23 in total

1.  Discontinuation of vasopressin before norepinephrine increases the incidence of hypotension in patients recovering from septic shock: a retrospective cohort study.

Authors:  Seth R Bauer; Joseph J Aloi; Christine L Ahrens; Jun-Yen Yeh; Daniel A Culver; Anita J Reddy
Journal:  J Crit Care       Date:  2010-06       Impact factor: 3.425

2.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

3.  Defining Sepsis Mortality Clusters in the United States.

Authors:  Justin Xavier Moore; John P Donnelly; Russell Griffin; George Howard; Monika M Safford; Henry E Wang
Journal:  Crit Care Med       Date:  2016-07       Impact factor: 7.598

4.  Rebranding of generic parenteral vasopressin: Effect on clinician practices and perceptions.

Authors:  Nicole Curtis; Jennifer Corapi; Russel Roberts; John W Devlin
Journal:  Am J Health Syst Pharm       Date:  2017-02-01       Impact factor: 2.637

5.  Hypotension Risk Based on Vasoactive Agent Discontinuation Order in Patients in the Recovery Phase of Septic Shock.

Authors:  Gretchen L Sacha; Simon W Lam; Abhijit Duggal; Heather Torbic; Anita J Reddy; Seth R Bauer
Journal:  Pharmacotherapy       Date:  2018-02-08       Impact factor: 4.705

6.  Evaluating Vasopressor Discontinuation Strategies in Patients With Septic Shock on Concomitant Norepinephrine and Vasopressin Infusions.

Authors:  Nadine Musallam; Diana Altshuler; Cristian Merchan; Bishoy Zakhary; Caitlin Aberle; John Papadopoulos
Journal:  Ann Pharmacother       Date:  2018-03-21       Impact factor: 3.154

7.  Discontinuation of Vasopressin Before Norepinephrine in the Recovery Phase of Septic Shock.

Authors:  Drayton A Hammond; Kelsey McCain; Jacob T Painter; Oktawia A Clem; Julia Cullen; Amy L Brotherton; Divyan Chopra; Nikhil Meena
Journal:  J Intensive Care Med       Date:  2017-06-15       Impact factor: 3.510

Review 8.  Epidemiology of severe sepsis.

Authors:  Florian B Mayr; Sachin Yende; Derek C Angus
Journal:  Virulence       Date:  2013-12-11       Impact factor: 5.882

9.  Prevalence and Predictors of Sepsis Death in Patients With Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction.

Authors:  Andrew M N Walker; Michael Drozd; Marlous Hall; Peysh A Patel; Maria Paton; Judith Lowry; John Gierula; Rowenna Byrom; Lorraine Kearney; Robert J Sapsford; Klaus K Witte; Mark T Kearney; Richard M Cubbon
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

10.  Incidence of Hypotension after Discontinuation of Norepinephrine or Arginine Vasopressin in Patients with Septic Shock: a Systematic Review and Meta-Analysis.

Authors:  Jae Uk Song; Jonghoo Lee; Hye Kyeong Park; Gee Young Suh; Kyeongman Jeon
Journal:  J Korean Med Sci       Date:  2020-01-06       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.